While the majority of the adults infected with hepatitis C virus are baby boomers-people between the ages of 51 and 71 years-Alaska is seeing a large spike in infection rates among young adults.
While the majority of the adults infected with hepatitis C virus (HCV) are baby boomers—people between the ages of 51 and 71 years—Alaska is seeing a large spike in infection rates among young adults.
A bulletin published by the State of Alaska Section of Epidemiology reported that there have been large increases of HCV infection rates among 18- to 29-year-olds. The largest reported change was an increase of 490% from 2011 to 2015 in southeastern Alaska. The gulf coast region of Alaska had the smallest change, but still reported an increase of 45%.
According to the bulletin, injection drug use (IDU) among young adults is likely the cause of the rising number of HCV-infected individuals between the ages of 18 and 29.
“Previous Alaska data on HCV prevalence demonstrated the majority of HCV cases reported were among ‘baby boomers,’” the authors of the report wrote. “The recent increase in HCV among young adults follows national HCV trends and we presume that our HCV-infected young adults share similar IDU risk factors.”
Although the number of reported HCV cases rose considerably across all age groups from 2011 to 2015 in Alaska, the increase was proportionally highest among young adults. In 2011, young adults represented 22% of all newly reported HCV cases, but in 2015, they represented 31% of new cases.
In addition, the Section of Epidemiology found that while most cases of new HCV infection across all age groups were in males, among young adults, females represented the most cases of new HCV infection.
The report noted that one of the ways to decrease IDU, and HCV infection, is through the use of syringe exchange programs.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More